SANDOZ BILASTINE DIN 02536269
Status: Marketed
Holder: SANDOZ CANADA INCORPORATED
Molecule: BILASTINE (BILASTINE MONOHYDRATE)
Available to quote
Health Canada record
| Active ingredient(s) | BILASTINE (BILASTINE MONOHYDRATE) 20 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | R06AX29 BILASTINE |
| Original market date | 22-Oct-2024 |
| Current status date | 22-Oct-2024 |
| Source | Health Canada DPD |
Establishment licence of the holder
Sandoz Canada Incorporated — licence 101370, currently licensed, last inspection rating C (2025-02-25).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 34253 | 2024-10-22 | Abbreviated New Drug Submission (ANDS) |